These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 12642128)

  • 21. De novo parallel design, synthesis and evaluation of inhibitors against the reverse transcriptase of human immunodeficiency virus type-1 and drug-resistant variants.
    Herschhorn A; Lerman L; Weitman M; Gleenberg IO; Nudelman A; Hizi A
    J Med Chem; 2007 May; 50(10):2370-84. PubMed ID: 17458947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel site.
    Himmel DM; Sarafianos SG; Dharmasena S; Hossain MM; McCoy-Simandle K; Ilina T; Clark AD; Knight JL; Julias JG; Clark PK; Krogh-Jespersen K; Levy RM; Hughes SH; Parniak MA; Arnold E
    ACS Chem Biol; 2006 Dec; 1(11):702-12. PubMed ID: 17184135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of human immunodeficiency virus type-1 reverse transcriptase by a novel peptide derived from the viral integrase.
    Oz Gleenberg I; Herschhorn A; Goldgur Y; Hizi A
    Arch Biochem Biophys; 2007 Feb; 458(2):202-12. PubMed ID: 17257575
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ribonuclease H/DNA Polymerase HIV-1 Reverse Transcriptase Dual Inhibitor: Mechanistic Studies on the Allosteric Mode of Action of Isatin-Based Compound RMNC6.
    Corona A; Meleddu R; Esposito F; Distinto S; Bianco G; Masaoka T; Maccioni E; Menéndez-Arias L; Alcaro S; Le Grice SF; Tramontano E
    PLoS One; 2016; 11(1):e0147225. PubMed ID: 26800261
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of mechanistically distinct inhibitors of HIV-1 reverse transcriptase through fragment screening.
    La J; Latham CF; Tinetti RN; Johnson A; Tyssen D; Huber KD; Sluis-Cremer N; Simpson JS; Headey SJ; Chalmers DK; Tachedjian G
    Proc Natl Acad Sci U S A; 2015 Jun; 112(22):6979-84. PubMed ID: 26038551
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision.
    Boyer PL; Sarafianos SG; Arnold E; Hughes SH
    J Virol; 2002 Sep; 76(18):9143-51. PubMed ID: 12186898
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structural optimization of N
    Monforte AM; De Luca L; Buemi MR; Agharbaoui FE; Pannecouque C; Ferro S
    Bioorg Med Chem; 2018 Feb; 26(3):661-674. PubMed ID: 29291935
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[Spiro[4"-amino-2",2" -dioxo-1",2" -oxathiole-5",3'-[2', 5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]]]-3-ethylthy mine.
    Sluis-Cremer N; Dmitrienko GI; Balzarini J; Camarasa MJ; Parniak MA
    Biochemistry; 2000 Feb; 39(6):1427-33. PubMed ID: 10684624
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors.
    Domaoal RA; Demeter LM
    Int J Biochem Cell Biol; 2004 Sep; 36(9):1735-51. PubMed ID: 15183341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of HIV-1 ribonuclease H activity by novel frangula-emodine derivatives.
    Tatyana K; Francesca E; Luca Z; Giovanni F; Cheng YC; Ginger ED; Enzo T
    Med Chem; 2009 Sep; 5(5):398-410. PubMed ID: 19534674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
    Taylor DL; Ahmed PS; Chambers P; Tyms AS; Bedard J; Duchaine J; Falardeau G; Lavallée JF; Brown W; Rando RF; Bowlin T
    Antivir Chem Chemother; 1999 Mar; 10(2):79-86. PubMed ID: 10335402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
    Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
    J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of the Zidovudine Resistance Mutations T215Y, M41L, and L210W in HIV-1 Reverse Transcriptase.
    Boyer PL; Das K; Arnold E; Hughes SH
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7184-96. PubMed ID: 26324274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr).
    Gleenberg IO; Herschhorn A; Hizi A
    J Mol Biol; 2007 Jun; 369(5):1230-43. PubMed ID: 17490682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.
    Boyer PL; Imamichi T; Sarafianos SG; Arnold E; Hughes SH
    J Virol; 2004 Sep; 78(18):9987-97. PubMed ID: 15331732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV-reverse transcriptase inhibition: inclusion of ligand-induced fit by cross-docking studies.
    Ragno R; Frasca S; Manetti F; Brizzi A; Massa S
    J Med Chem; 2005 Jan; 48(1):200-12. PubMed ID: 15634014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains.
    Himmel DM; Das K; Clark AD; Hughes SH; Benjahad A; Oumouch S; Guillemont J; Coupa S; Poncelet A; Csoka I; Meyer C; Andries K; Nguyen CH; Grierson DS; Arnold E
    J Med Chem; 2005 Dec; 48(24):7582-91. PubMed ID: 16302798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture.
    Archer RH; Dykes C; Gerondelis P; Lloyd A; Fay P; Reichman RC; Bambara RA; Demeter LM
    J Virol; 2000 Sep; 74(18):8390-401. PubMed ID: 10954539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The processivity of DNA synthesis exhibited by drug-resistant variants of human immunodeficiency virus type-1 reverse transcriptase.
    Avidan O; Hizi A
    Nucleic Acids Res; 1998 Apr; 26(7):1713-7. PubMed ID: 9512543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis, and anti-HIV-1 activity of 1-aromatic methyl-substituted 3-(3,5-dimethylbenzyl)uracil and N-3,5-dimethylbenzyl-substituted urea derivatives.
    Sakakibara N; Baba M; Okamoto M; Toyama M; Demizu Y; Misawa T; Kurihara M; Irie K; Kato Y; Maruyama T
    Antivir Chem Chemother; 2015 Feb; 24(1):3-18. PubMed ID: 26149262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.